公开(公告)号：US20160000811A1

公开(公告)日：2016-01-07

申请号：US14768744

申请日：2014-02-18

Applicant: NOVARTIS AG ,  KYORIN PHARMACEUTICAL CO. LTD.

Inventor： Peter GERGELY ,  Kazuhiko KURIYAMA

IPC: A61K31/661 ,  C07C323/32 ,  C07F9/09 ,  A61N5/10 ,  A61K31/7076 ,  A61K31/255 ,  A61K31/664 ,  A61K35/28 ,  A61K31/145

CPC classification number: A61K31/661 ,  A61K31/137 ,  A61K31/145 ,  A61K31/255 ,  A61K31/519 ,  A61K31/664 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/28 ,  A61K38/13 ,  A61K2035/122 ,  A61K2035/124 ,  A61N5/10 ,  C07C323/32 ,  C07F9/094 ,  A61K2300/00

Abstract: The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable.

Abstract translation: 本发明涉及一种治疗患有血液恶性肿瘤的外周血移植干细胞造血干细胞移植（HSCT）的患者的方法，对于严重急性移植物抗宿主病（GVHD）的风险相当可观。

公开(公告)号：US20200306244A1

公开(公告)日：2020-10-01

申请号：US16311366

申请日：2017-06-20

Applicant: NOVARTIS AG

Inventor： Jennifer Leslie HARRIS ,  Peter GERGELY ,  Jun LIU ,  Eric SVENSSON

IPC: A61K31/497 ,  C07K16/28 ,  A61K9/00 ,  A61P13/12 ,  A61P17/00

Abstract: The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also provides a method for the treatment of fibrosis, a pharmaceutical combination comprising a wnt inhibitor of formula (I) and a second active ingredient for use in the treatment of fibrosis and also the use of a wnt inhibitor of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of fibrosis and fibrosis mediated disorders.